Home > Platform Technologies > Analgesics > Program Reports

Cytogel has completed pre-clinical toxicology and safety studies, filed an IND application, completed a first in man Phase 1 study and has received clearance to begin Phase 2 clinical studies for CYT-1010. The completed Phase 1 study has provided an early demonstration of pharmacodynamic activity in pain relief, in addition to demonstrating safety and assessing pharmacokinetics. The Phase 2 program will commence shortly.